Stephanie E. Hughes, P.E. (408)
|
|
- Isabella Dawson
- 5 years ago
- Views:
Transcription
1 Stephanie E. Hughes, P.E. (408)
2 Learning Objectives Understand the environmental and social burdens of pharmaceutical waste Recognize the complexity of pharmaceutical pollution Distinguish between upstream and downstream solutions Learn how to minimize the risks associated with hospice pharmaceuticals Gain resources to advocate for proper medication disposal with hospice patients.
3 Your instructor and this presentation have been approved by the California Board of Registered Nurses All participants are eligible to obtain a certificate for 1.0 contact hour of continuing education
4 Certification of Completion Proper Disposal of Unwanted Medications 1.0 Contact Hour This is to certify that: First and Last Name Has completed the above educational training. Provider approved by the California Board of Registered Nursing, Provider #CEP for 1.0 Contact Hours. This certificate must be retained by the licensee for a period of four years after the course ends. Stephanie Hughes, Instructor Date
5 Today s Discussion Introduce myself and the funders of today s webinar Explore impacts and unintended consequences of unused pharmaceuticals Review a local inventory of unwanted pharmaceuticals Discuss upstream and downstream solutions What you can do to help families of hospice patients
6 About me, Stephanie Hughes Registered Chemical Engineer B.S. Chemical Engineering, University of Minnesota M.S. Chemical Engineering, Stanford M.S. Environmental Engineering, Stanford More than 20 years of experience in environmental engineering and water quality Consultant to wastewater agencies throughout California regarding pollutant source identification and pollution prevention Lecturer at Santa Clara University, Dept. of Environmental Studies and Science
7 Funding today s CHAPCA webinar:
8 Provides wastewater conveyance and treatment services to residential, industrial and commercial customers throughout unincorporated Sacramento County; the cities of Citrus Heights, Elk Grove, Folsom, Rancho Cordova, Sacramento and West Sacramento; and the communities of Courtland and Walnut Grove.
9 BAPPG represents Bay Area sewage treatment plants Serve 7 million people in 9-county Bay Area Treat domestic, commercial, and industrial wastewater Collaborate to conduct educational programs to ensure long-term stewardship of the San Francisco Bay Estuary.
10 39 wastewater treatment plants discharge into San Francisco Bay and treat 620,000,000 gallons of wastewater every day from homes, industry and businesses
11 In the USA, 16,000 wastewater treatment plants discharge into local water bodies and treat billions of gallons of wastewater every day from homes, industry and businesses
12 Treated wastewater is released into a local water body or recycled / reclaimed for irrigation and other purposes
13 1. Childhood poisoning 2. Theft, Abuse, Misuse 3. Excessive accumulation of unwanted drugs 4. Unintended environmental exposure 5. Inappropriate international donations
14 With increases in prescriptions and population, the issue will only grow Overall Population growth in the US between 1992 and 2003 Increased 13% Number of prescriptions written for noncontrolled drugs Increased 57% Number of prescriptions filled for controlled drugs Increased 154% National Center on Addiction and Substance Abuse at Columbia University (CASA)
15 1. Childhood Poisoning 2,500,000 human exposures in 2005 (AAPCC) 51% of all poisoning exposures were due to pharmaceuticals 41.6% involved children less than 6 years of age 14.9% involved minors aged 6 to 19 years 34 % involved adults over 20 years of age
16 2. Increased Abuse Number of people admitted to hospitals abusing controlled prescription drugs Increased 90% Among 12 to 17 year olds Increased 203% Among those greater than 18-years old Increase 78% From 1992 to 2003, based on a study from the National Center on Addiction and Substance Abuse at Columbia University (CASA)
17 Abuse and Misuse From 1992 to 2003 Teenage use of Alprazolam, oxycodone, and methylphenidate Increased 212% Teenager addicted to opioids, CNS depressants or stimulants Increased 15% Total # of Americans abusing controlled prescription drugs 15.1 million Exceeds the combined number abusing: cocaine (5.9 million), hallucinogens (4.0 million), inhalants (2.1 million), heroin (.3 million).
18 Prescription Drug Abuse County ME Substances involved in Substance Abuse Questions from Top 10 Categories Only Northern New England Poison Center's SASRS Database Count N = 68,792 Group Name Opioids Benzodiazepines/Benzodiazepine-like Non-Opioid Analgesics without sedatives (aspirin, Tylenol ) Unknown Drug Antidepressants Cardiovascular (Heart) Skeletal Muscle Relaxants Stimulants and Street Drugs Antibiotics and Other Anti-infectives, Vaccines Other Drug (Chemotherapy, Radiopharmaceuticals, Diagnostic, Hormones, Antidiabetic, Antithyroid) Year
19 Crime The Federal ONDCP recognizes the connection between the accumulation of medicines in the home and the potential for diversion and abuse. Hydrocodone and oxycodone are implicated in 28% of all drug related crime. Methylphenidate and dextromethorphan are implicated in 19% of all drug related crime.
20 3. Household Accumulations Number of Medications Respondent s Household Members Have Number of P or NP Meds Prescription Nonprescription % 11.7% % 13.0% % 15.6% % 12.6% % 23.8% % 23.3% Mean Std. Dev (3.8) (4.4) MEDICATION DISPOSAL SURVEY Report (2010)
21 4. Environmental Exposures Correlate to Endocrine Disruption and Toxicity Prozac and Luvox induce spawning in bivalves at significantly low concentrations Fluoxetine enhances the release of ovary-stimulating hormones in crayfish Diclofenac has been proven to be toxic to vultures, decimating populations in the Indian subcontinent due to its ubiquitous use in cattle
22 Primary Sex Characteristic Example: Testicular Cell Tissue normal male flounder intersex male flounder Matthiessen P, Allen YT, Allchin CR, Feist SW, Kirby MF, Law RJ, Scott AP, Thain JE, Thomas KV. (1998) Oestrogenic endocrine disruption in flounder (Platichthys flesus L.) from United Kingdom estuarine and marine waters. Science Series, Technical Report No Centre for Environment, Fisheries and Aquaculture Science]
23 Secondary Sex Characteristics Male Female Female with male characteristics Secondary sex characteristics may also be affected by EDCs. Above left is a male fathead minnow. Above middle is a female fathead minnow. Far right is a female minnow that developed male nose markings following exposure to androgenic EDCs. (Provided by G. Ankley, U.S. EPA, Duluth, MN)
24 More examples SSRIs elicit aggressive behavior in lobsters, causing subordinates to engage in fighting against the dominant member, and reducing the propensity to retreat induce spawning in shellfish Calcium channel blockers (lowers blood pressure) dramatically inhibit sperm activity in Atlantic croaker Clofibrate (lowers cholesterol) cause high production of estrogen in juvenile zebra fish at concentrations present in Chesapeake Bay
25 5. Inappropriate Humanitarian Drug Donations Armenia, ,000 tons of drugs and medical supplies worth US$ 55 million were sent. It took 50 people six months to gain a clear picture of the drugs that had been received. 8% had expired on arrival 4% were destroyed by frost Of the remaining 88% only 30% were easy to identify 42% were relevant for an emergency situation.
26 Inappropriate Humanitarian Drug Donations France, 1991 Pharmaciens Sans Frontières collected 4 million kg of unused drugs from 4,000 pharmacies Sorted in 88 centers around the country Only about 20% could be used for international aid programs Remaining 80% incinerated instead
27
28 Based on a Bay Area survey, these are the top medications needing disposal In 2009, surveyed 3 out of 126 Bay Area drop-off sites, and gathered 2 months of disposed material.
29
30
31 Medications by Sub-therapeutic Class Top Sub-therapeutic Class Therapeutic Class % Analgesics CNS 12.4% Bronchodilators Respiratory 12.4% Dermatological agents Topical 5.4% Cardiovascular agents NTA Cardiovascular 3.9% Antipsychotics Psychotherapeutic 3.8% Anxiolytics, sedatives, and hypnotics Psychotherapeutic 3.5% Antihistamine Respiratory 2.7% Nasal preparations Topical 2.3% Vitamins Nutritional 2.1% Antidepressants Psychotherapeutic 2.1% Laxatives Gastrointestinal 2.1% Minerals and electrolytes Nutritional 2.1% Respiratory agents NTA Respiratory 2.1% Ophthalmic preparations Topical 2%
32 Most Common Medications Returned
33 Powders 3% Injectables 4% Ointments 6% Inhalers 2% Suppositories 1% Patch 1% Dosage Form Liquids 26% Pills 57%
34 Expired? 21% Expired Not Expired 79%
35 Packaging is a HUGE part of the disposed volume What are the disposal implications?
36 Upstream vs. Downstream
37 What are upstream solutions? Manufacturer product stewardship Consider fate of products Pollution Prevention Controlling at the source
38 Cradle to Cradle Medicine In theory, waste occurs when the prescription isn t effective. If we get to the point where we have no leftover drugs, will that lead to improved therapeutic outcomes? Learning about what is unused will improve the quality of medical care
39 Medical staff are part of the UPSTREAM solution Moderate prescribing and dispensing patterns of p.r.n. medications. At discharge or transfer to another facility, give remaining medications to the patient or new facility to use. Single Dose electronic dispensing
40 What about downstream? What should one do with unwanted medications? Should we flush down the toilet or not? It depends
41 There are major concerns with flushing Sewage systems are not designed to remove these medicines from water 80 percent of US waterways contain measurable amounts of human medicines. Fish and other aquatic animals have shown adverse effects from pharmaceuticals and other chemicals
42 Wastewater treatment plants are designed to remove certain pollutants Examples: human waste, food waste, biodegradable soaps but not others, such as Pharmaceuticals Anti-bacterial soap Metals Pesticides
43 Meanwhile, due to potential single-dose toxicity, the FDA considers especially harmful drugs to be flushable Certain medicines may be especially harmful and, in some cases, fatal in a single dose if they are used by someone other than the person the medicine was prescribed for. For this reason, a few medicines have special disposal directions that indicate they should be flushed down the sink or toilet after the medicine is no longer needed.
44 The FDA recommends flushing these meds: Medicine Active Ingredient Abstral, tablets Actiq, oral transmucosal lozenge * Avinza, capsules (extended release) Buprenorphine Hydrochloride,, Naloxone Hydrochloride, tablets Butrans, transdermal patch system Daytrana, transdermal patch system Demerol, tablets and oral solution * Diastat/Diastat AcuDial, rectal gel Dilaudid, tablets and oral liquid* Dolophine Hydrochloride, tablets * Duragesic, patch (extended release) * Embeda, capsules (extended release) Fentanyl Fentanyl Citrate Morphine Sulfate Buprenorphine Hydrochloride, Naloxone Hydrochloride Buprenorphine Methylphenidate Meperidine Hydrochloride Diazepam Hydromorphone Hydrochloride Methadone Hydrochloride Fentanyl Morphine Sulfate; Naltrexone Hydrochloride
45 FDA s List, cont d (page 2 of 3) Medicine Active Ingredient Exalgo, tablets (extended release) Fentora, tablets (buccal) Kadian, capsules (extended release) Hydromorphone Hydrochloride Fentanyl Citrate Morphine Sulfate Methadone Hydrochloride, oral solution* Methadone Hydrochloride Methadose, tablets * Morphine Sulfate, tablets (immediate release) * Morphine Sulfate, oral solution * MS Contin, tablets (extended release) * Nucynta ER, tablets (extended release) Onsolis, soluble film (buccal) Opana, tablets (immediate release) Opana ER, tablets (extended release) Methadone Hydrochloride Morphine Sulfate Morphine Sulfate Morphine Sulfate Morphine Sulfate Fentanyl Citrate Oxymorphone Hydrochloride Oxymorphone Hydrochloride
46 FDA s List, cont d (page 3 of 3) Medicine Oxecta, tablets (immediate release) Oxycodone Hydrochloride, capsules Oxycodone Hydrochloride, oral solution Oxycontin, tablets (extended release) * Percocet, tablets * Active Ingredient Oxycodone Hydrochloride Oxycodone Hydrochloride Oxycodone Hydrochloride Oxycodone Hydrochloride Acetaminophen; Oxycodone Hydrochloride Percodan, tablets * Suboxone Xyrem, oral solution Zubsolv, tablets Aspirin; Oxycodone Hydrochloride Buprenorphine Hydrochloride, Naloxone Hydrochloride Sodium Oxybate Buprenorphine Hydrochloride, Naloxone Hydrochloride *These medicines have generic versions available or are only available in generic formulations. List revised by FDA: November 2013
47 If we aren t flushing, what are we doing? Encourage families to collect unwanted or expired medications and bring to a local collection program These medications are incinerated Eliminates impact of drain disposal Eliminates impact of landfilling
48 Take-back programs are available throughout California and Nevada Photo: Michael Macor, The Chronicle / SF
49 Today I will share a number of resources with you: Sacramento/Yolo Counties San Francisco Bay Area Alameda, Sacramento, and Santa Clara Counties Southern California (Los Angeles, Orange County, Riverside, and San Diego) Southern Nevada
50 Earth911.com Type in medication or drugs along with zip code
51 Example for San Jose, 95126
52 Sacramento and Yolo Counties:
53 San Francisco Bay Area: Type in medication or drugs along with zip code
54 For Contra Costa, Sacramento, Santa Clara, and Yolo Counties, go to:
55 Programs in these counties are being managed by the California Product Stewardship Council thanks to government grants.
56 For Southern California:
57 Southern Nevada:
58
59 When advising patients and their families to collect pharmaceuticals Consolidate pills into one container Leave ointments and liquids in original container Dispose of vitamins in the garbage
60 What about controlled substances? The DEA has JUST modified their controlled substances regulations which should expand the collection options: Take-back programs Mail-back programs Collection receptacles
61 DEA s Final Rule on Disposal of Controlled Substances Published September 9, 2014 in the Federal Register Effective October 9, ex.html Google: DEA drug diversion
62 This one-page summary has been provided to all webinar participants
63 At the DEA Drug Diversion Site:
64 Hospice-specific language from the Federal Register
65 Continued
66 Long Term Care Facility Language
67 The future of pharmaceutical disposal? Many jurisdictions are seeking manufacturer-funded take-back programs Local efforts The County of Alameda King County (Seattle-area), Washington
68 The California Pharmaceutical Stewardship Bill If enacted, this would require pharmaceutical manufacturers to develop and manage pharmaceutical collection programs in California. Authored by Hannah-Beth Jackson, Santa Barbara
69 What else can you do? Hold and reduce! Hold medications during the acute hospitalization period of up to 10 days. Continue to examine prescribing patterns decrease quantities in the event of unexpected changes discontinue medications to help eliminate unused and wasted medications
70 As a hospice professional, you can: Reduce unused accumulations Understand proper medication disposal Know where local take back sites are located Provide information to patients and their families Photo: Michael Macor, The Chronicle / SF
71 Other efforts that you and your patients can help our waterways Eliminate the use of triclosan-containing antibacterial soaps and other products Do NOT flush any wipes ( flushable or otherwise)
72
73 Products Containing Triclosan Hand soap Dish-washing products Laundry detergents and softeners Plastics (e.g., toys, cutting boards) Toothpaste Deodorants and antiperspirants Cosmetics Hair conditioners Impregnated sponges Pesticides (as an inert ingredient)
74 Triclosan is in Our Environment U.S. Geological Society found triclosan in 57% of tested U.S. waterways Acutely and chronically toxic to aquatic organisms Bioaccumulates in fish and human tissue Found in human breast milk Degrades into other toxic (dioxin-like) compounds May provide false sense of security
75 May Create an Antibiotic Resistance in Bacteria Triclosan interferes with a specific bacterial enzyme Some antibiotics targets same enzyme Example: tuberculosis antibiotic Overuse of triclosan may lead to antibacterial resistance to some of our antibiotics Antiseptics (e.g., ethyl alcohol, peroxides) simply break open the cell wall, so cannot affect antibiotic resistance Use of ethyl alcohol or peroxides is fine!
76 Are These Antibacterial Products Necessary? American Medical Association No data exist to support their efficacy Mayo Clinic a false sense of security Center for Science in the Public Interest's project on antibiotic resistance never been shown to be superior, to my knowledge, to regular soap and water"
77 Alternatives?
78
79
80 What everyone can do! Commit to a healthy lifestyle Focus on prevention Dispose unwanted medications at take-back sites Purchase drugs in small amounts Ask for medications with low environmental impact All health providers should know what to do with unused medications Take them back!
81 Consider the environment as part of our overall health care system Treating the environment and healthcare as an integral system could greatly clarify where and how to invest resources to achieve optimal outcomes. Improvements in either can lead to collateral in improvements in the other. - Christian Daughton, PhD
82 Reducing pharmaceuticals entering the environment at all levels of healthcare delivery will have personal, social and environmental benefits
83 Acknowledgements Dr. Joel Kreisberg, DC Executive Director, Teleosis Institute
Disposal by Flushing of Certain Unused Medicines: What
Disposal by Flushing of Certain Unused Medicines: What You Should Know Drugs Page 1 of 5 Disposal by Flushing of Certain Unused Medicines: What You Should Know Overview Frequently Asked Questions List
More informationDisposal of Unused Medicines: What You Should Know
1 of 8 3/12/16 11:14 PM U.S. Food and Drug Administration Protecting and Promoting Your Health Disposal of Unused Medicines: What You Should Know Topics on this page Overview List of Medicines Recommended
More informationDisposal of Unused Medicines: What You Should Know
1 of 8 04/27/2016 1:37 AM U.S. Food and Drug Administration Protecting and Promoting Your Health Disposal of Unused Medicines: What You Should Know Topics on this page (http://www.fda.gov/aboutfda/aboutthiswebsite
More informationHow To Green My Pharmacy. Prepared and presented by Luna El Bizri,Pharm-D, Community Pharmacist
How To Green My Pharmacy Prepared and presented by Luna El Bizri,Pharm-D, Community Pharmacist Learning Objectives At the end of this presentation, pharmacists will be able to : 1. Understand the negative
More informationPharmacy Medical Necessity Guidelines: Opioid Analgesics
Pharmacy Medical Necessity Guidelines: Effective: January 1, 2019 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
More informationAddressing Drug Diversion
Webinar Objectives Addressing Drug Diversion Bernice Burkarth, MD, HMDC, FAAHPM BBurkarth@treasurehealth.org October12, 2017 At the completion of this Webinar, participants will be able to: Identify tools
More informationCopyright 2018 DisposeRx, Inc. All rights reserved.
30 seconds breaks the chain of abuse and pollution!!! The problem starts at home; the solution: DisposeRx has developed a simple to use, inhome disposal solution for unused, unwanted, expired and/or off-therapy
More informationBlueprint for Prescriber Continuing Education Program
CDER Final 10/25/11 Blueprint for Prescriber Continuing Education Program I. Introduction: Why Prescriber Education is Important Health care professionals who prescribe extended-release (ER) and long-acting
More informationMethadone. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.41 Subject: Methadone Page: 1 of 8 Last Review Date: March 18, 2016 Methadone Description Dolophine
More informationEmbeda. Embeda (morphine sulfate and naltrexone hydrochloride) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.39 Subject: Embeda Page: 1 of 6 Last Review Date: March 18, 2016 Embeda Description Embeda (morphine
More informationMorphine Sulfate Hydromorphone Oxymorphone
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.02.33 Subject: Morphine Drug Class Page: 1 of 8 Last Review Date: June 19, 2015 Morphine Sulfate Hydromorphone
More informationSecure Medicine Return Regulations King County, Washington
Secure Medicine Return Regulations King County, Washington Board of Health Chapter 11.50 New law to create a sustainably financed, county-wide secure medicine return system SMR-090413 King County Passes
More informationLong-Acting Opioid Analgesics
Market DC Long-Acting Opioid Analgesics Override(s) Prior Authorization Step Therapy Quantity Limit Approval Duration Initial request: 3 months Maintenance Therapy: Additional prior authorization required
More informationLong-Acting Opioid Analgesics
Market DC Long-Acting Opioid Analgesics Override(s) Prior Authorization Step Therapy Quantity Limit Approval Duration Initial request: 3 months Maintenance Therapy: Additional prior authorization required
More informationDrug Information Common to the Class of Extended-Release and Long-Acting Opioid Analgesics (ER/LA opioid analgesics) Avinza Butrans
FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics 7/9/2012 Drug Information Common to the Class of Extended-Release and Long-Acting Opioid Analgesics (ER/LA
More informationXyrem (Sodium Oxybate)
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Criteria Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationPrior Authorization Guideline
Guideline GL-35952 Opioid Quantity Limit Overrides Formulary OptumRx Formulary Note: Approval Date 7/10/2017 Revision Date 7/10/2017 Technician Note: P&T Approval Date: 2/16/2010; P&T Revision Date: 7/12/2011
More information1/29/2013. Schedule II Controlled Substances: Basics and Beyond. Controlled Substances. Controlled Substances, Schedule I
chedule II Controlled ubstances: Basics and Beyond James L. Besier, Ph.D., R.Ph., FAHP Adjunct Associate Professor College of Nursing Adjunct Assistant Professor James L. Winkle College of Pharmacy University
More informationER/LA Opioid REMS: Achieving Safe Use While Improving Patient Care
ER/LA Opioid REMS: Achieving Safe Use While Improving Patient Care In August 2014, the Food and Drug Administration (FDA) updated the Extended- Release/Long Acting Opioids REMS Blueprint (BP). CO*RE has
More informationLong-Acting Opioid. Policy Number: Last Review: 12/2017 Origination: 09/2013 Next Review: 09/2018
Long-Acting Opioid Policy Number: 5.02.519 Last Review: 12/2017 Origination: 09/2013 Next Review: 09/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for long-acting
More informationProper Disposal of Medications
Proper Disposal of Medications The Risks of Improper Disposal and the Benefits of Take-Back Programs Tag Words: Medication; Disposal of Medications; Prescription Drugs; Over the Counter Drugs Authors:
More informationA guide to proper disposal of prescription and over-the-counter medicines.
A guide to proper disposal of prescription and over-the-counter medicines. Safe Disposal for Safer Homes The SafeMeds Program, formally West Michigan Take Back Meds Program, is a joint effort between local
More informationTechnician Training Tutorial: Safety Considerations with Opioids
(Page 1 of 5) Technician Training Tutorial: Safety Considerations with Opioids Opioids as a drug class are considered to be high-alert drugs. This class includes codeine, methadone, oxycodone, etc. When
More informationCapital BlueCross Open/Closed Formulary Update (1 st Quarter 2017)
Capital BlueCross Open/Closed Formulary Update (1 st Quarter 2017) The Capital BlueCross formulary is a reference list of prescription drugs that contains a wide range of generic and brand drugs that have
More informationOpioid Prescribing Guidelines for Patients in the Emergency Department
Opioid Prescribing Guidelines for Patients in the Emergency Department and Immediate Care Centers These guidelines are meant to assist clinicians in treating patients with acute and chronic pain in the
More informationCarefirst. +.V Family of health care plans
Family of health care plans Prior Authorization Form 1361M Opioids ER MME Limit and Post Limit This fax machine is located in a secure location as required by HPAA regulations. Complete/review information,
More informationOpioid Management Program May 2018
Opioid Management Program May 2018 What Is the Opioid Management Program? This program is based on guidelines developed by the U.S. Centers for Disease Control and Prevention (CDC). It consists of daily
More information20/0.8mg, 30/1.2mg, Films 90 MME/day Belbuca (buprenorphine) 75mcg, 150mcg, 300mcg, 450mcg 60 units per 90 days
Pre - PA Allowance Quantity Extended Release Tablets or Capsules 90 MME/day Medication Strength Avinza (morphine) 60mg, 75mg, 90mg Embeda (morphine /naltrexone) 50/2mg, 60/2.4mg, 80/3.2mg Exalgo (hydromorphone)
More informationDemerol (meperidine oral tablet, oral solution), Meperitab (oral tablet)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subsection: Analgesics and Opioids Original Policy Date: May 8, 2015 Subject: Meperidine Page: 1 of 5 Last
More informationPharmaceuticals from Households: A Return Mechanism (PH:ARM)
Pharmaceuticals from Households: A Return Mechanism (PH:ARM) A Washington State Pilot Program Emma Johnson Washington State Department of Ecology Solid Waste and Financial Assistance Program April 24,
More informationPrescription Drug Abuse: Colorado and Nationwide
Prescription Drug Abuse: Colorado and Nationwide Eric Lavonas, MD Associate Director, Rocky Mountain Poison and Drug Center Associate Professor, University of Colorado School of Medicine 1 What s the Problem?
More informationSession VI. Presenter Disclosure Information. Learning Objectives for Session VI. Prescribing Information. Prescribers Must Be Knowledgeable
SAFE Opioid Prescribing Strategies. Assessment. Fundamentals. Education 4 6pm SPEAKERS Charles Argoff, MD, FABPM Michael Brennan, MD, FACP, FASAM Jeffrey Gudin, MD Presenter Disclosure Information The
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Controlled Substance Analgesic and Narcotic Antagonist Quantity Limitations Table of Contents Coverage Policy... 1 General Background... 6 Coding/Billing
More information9/5/2011. Outline. 1. Past and Current Trends re: RX Abuse 2. Diversion Methods 3. Regulatory Reporting Requirements 4. Q/A
Prescription Drug Abuse Crises Outline 1. Past and Current Trends re: RX Abuse 2. Diversion Methods 3. Regulatory Reporting Requirements 4. Q/A 1 1970s 1980s 2 The 1990s OXYCODONE Oxycodone/APAP OxyContin
More informationOpioid Management Program October 2018
Opioid Management Program October 2018 What Is the Opioid Management Program? This program is based on guidelines developed by the U.S. Centers for Disease Control and Prevention (CDC). It consists of
More informationGeneric Label Name Drug Strength Dosage Form Example Product (s) MME/Unit ACETAMINOPHEN WITH CODEINE
STATE OF TENNESSEE DEPARTMENT OF FINANCE AND ADMINISTRATION DIVISION OF HEALTH CARE FINANCE AND ADMINISTRATION BUREAU OF TENNCARE 3 Great Circle Road NASHVILLE, TENNESSEE 37243 This notice is to advise
More informationNucynta IR/ Nucynta ER (tapentadol immediate-release and extendedrelease)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Nucynta Page: 1 of 7 Last Review Date: March 18, 2016 Nucynta Description Nucynta IR/ Nucynta
More informationPreventing Prescription Opioid Misuse Among Student Athletes
Preventing Prescription Opioid Misuse Among Student Athletes Massachusetts is in the midst of an opioid epidemic. Athletes in particular, due to their risk of injury and the resulting pain, may be at risk
More informationOpioids: Use, Abuse and Cause of Death. Jennifer Harmon Assistant Director - Forensic Chemistry Orange County Crime Laboratory
Opioids: Use, Abuse and Cause of Death Jennifer Harmon Assistant Director - Forensic Chemistry Orange County Crime Laboratory jharmon@occl.ocgov.com Opioid: Any psychoactive chemical that resembles morphine
More informationHealthy Aging MEDICATIONS & ALCOHOL
Healthy Aging MEDICATIONS & ALCOHOL Family, work, hobbies, travel... ALL this can keep you busy! Don t let problems with medications or alcohol slow you down. Take a few simple steps to get the most out
More informationPrior Authorization for Opioid Products Indicated for Pain Management
Kansas Medical Assistance Program PA Phone 800-933-6593 PA Fax 800-913-2229 Amerigroup PA Pharmacy Phone 855-201-7170 PA Pharmacy Fax 800-601-4829 Sunflower PA Pharmacy Phone 877-397-9526 PA Pharmacy Fax
More informationPharmacological Pain Management, the Evolving Role of Opioids, and Improving Education of Health Care Providers
Pharmacological Pain Management, the Evolving Role of Opioids, and Improving Education of Health Care Providers James P. Rathmell, M.D. Chair, Department of Anesthesiology, Perioperative and Pain Medicine
More informationNew Hampshire Healthy Families CLINICAL POLICY
New Hampshire Healthy Families CLINICAL POLICY DEPARTMENT: Pharmacy DOCUMENT NAME: Opioid Analgesics PAGE: 1 o f 6 REFERENCE NUMBER: NH.PPA.13 EFFECTIVE DATE: 6/1/2016 REPLACES DOCUMENT: N/A RETIRED: REVIEWED:
More informationQUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA
DRUG CLASS QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA EXTENDED-RELEASE OPIOID ANALGESICS BRAND NAME (generic) ARYMO ER (morphine sulfate extended-release tablets) AVINZA (morphine extended-release
More information: Opioid Quantity Limits
March 7, 2017 2017-09: Opioid Quantity Limits The Louisiana Department of Health (LDH), in conjunction with the Louisiana Medicaid Drug Utilization Review (DUR) Board, has revised quantity limits for selected
More informationOpioid Harm Reduction
Opioid Harm Reduction Lucas G. Hill, PharmD Clinical Assistant Professor, The University of Texas at Austin College of Pharmacy Clinical Pharmacist, CommUnityCare FQHCs Director, Operation Naloxone Mark
More informationSafe Medication Disposal A white position paper Pennsylvania Pharmacists Association February 8, 2009
Safe Medication Disposal A white position paper Pennsylvania Pharmacists Association February 8, 2009 Background and Situation Analysis: Consumers are rightly confused about what to do with their unwanted
More informationMEDICARE Program Policies & Procedures POLICY NUMBER: Medicare D-111
POLICY: Medicare Part D Formulary-Level Cumulative Opioid and Opioid/Buprenorphine POS Edits MEDICARE Program Policies & Procedures POLICY NUMBER: Medicare D-111 Policy for contracts H3351, S3521 and H3335
More informationTechnician Tutorial: Scheduled Drugs
(Page 1 of 8) Technician Tutorial: Scheduled Drugs In the U.S., the federal Controlled Substances Act (CSA) regulates controlled substances. The U.S. Drug Enforcement Administration (DEA), which is a part
More informationHOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain
Due to the high level of prescription drug use and abuse in Lake County, these guidelines have been developed to standardize prescribing habits and limit risk of unintended harm when prescribing opioid
More informationOpioid Analgesics. Recommended starting dose for opioid-naïve patients
Opioid Analgesics Goals: Restrict use of opioid analgesics to OHP-funded conditions with documented sustained improvement in pain and function and with routine monitoring for opioid misuse and abuse. Promote
More informationEducation Program for Prescribers and Pharmacists
Transmucosal Immediate Release Fentanyl (TIRF) Products Risk Evaluation and Mitigation Strategy (REMS) Education Program for Prescribers and Pharmacists Products Covered Under this Program Abstral (fentanyl)
More informationMark W. Caverly, Chief Liaison and Policy Section
DEA Issues: An Update Harold Rogers National Prescription Drug Monitoring Meeting Meeting September 24 25, 2009 Mark W. Caverly, Chief Liaison and Policy Section Prescription Drug Abuse Prescription Drug
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Transmucosal Immediate Release Fentanyl Products Reference Number: CP.CPA.211 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder
More informationAbuse, Misuse, and Diversion of Prescription Opioids: Evaluating the Problem and Proposed Solutions
Abuse, Misuse, and Diversion of Prescription Opioids: Evaluating the Problem and Proposed Solutions Eric Lavonas, MD, FACEP, FACMT, FAACT Associate Director, Rocky Mountain Poison & Drug Center Denver
More informationNATL. II. Health Net Approved Indications and Usage Guidelines: Diagnosis of cancer AND. Member is on fentanyl transdermal patches AND
Coverage of drugs is first determined by the member s pharmacy or medical benefit. Please consult with or refer to the Evidence of Coverage document I. FDA Approved Indications: The management of breakthrough
More informationCollecting Unwanted Medications: The Legal & Safe Way
Collecting Unwanted Medications: The Legal & Safe Way Lynn Rubinstein Northeast Recycling Council, Inc. January 28, 2009 Background What is NERC? Non-profit 10 Northeast states Mission: environmental sustainability
More informationOpioid Analgesic Treatment Worksheet
Opioid Analgesic Treatment Worksheet Aetna Better Health of Louisiana Fax: 1 844 699 2889 www.aetnabetterhealth.com/louisiana/providers/pharmacy LA Legacy Fee for Service (FFS) Medicaid Fax: 1 866 797
More informationSession II. Learning Objectives for Session II. Key Principles of Safe Prescribing. Benefits and Limitations of ER/LA Opioids
Learning Objectives for Session II Session II Best Practices for How to Start Therapy with ER/LA Opioids, How to Stop, and What to Do in Between Upon completion of this module, the participants will be
More informationFAQs on Proper Disposal of Drugs
FAQs on Proper Disposal of Drugs In the past, you might have been told it was best to discard medications by flushing them. What has changed? There is a new awareness about the potential harmful effects
More informationIntroduction for the FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics
Introduction for the FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics In April 2011, FDA announced the elements of a Risk Evaluation and Mitigation Strategy
More informationFENTANYL CITRATE TRANSMUCOSAL UTILIZATION MANAGEMENT CRITERIA
FENTANYL CITRATE TRANSMUCOSAL UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: BRAND (generic) NAMES: HICL = H3AT Fentanyl citrate transmucosal Actiq (fentanyl citrate) lozenge on a handle 200, 400, 600, 800,
More information10 BEFORE THE MEDICAL BOARD OF CALIFORNIA Kimberly Kirchmeyer ("Complainant") brings this Accusation solely in her official
2 3 4 5 6 7 XAVIER BECERRA Attorney General of California MATTHEW M. DAVIS Supervising Deputy Attorney General JOHNS. GATSCHET Deputy Attorney General State Bar No. 244388 California Department of Justice
More informationAnyone Can Become Addicted. Anyone.
Anyone Can Become Addicted. Anyone. PAStop.org Family Toolkit Seeking Drug Abuse Treatment: Know What to Ask Trying to identify the right treatment programs for a loved one can be a difficult process.
More informationAPPROVED PA CRITERIA. Initial Approval: January 10, 2018 Revised Dates: April 11, 2018 CRITERIA FOR PRIOR AUTHORIZATION
Initial Approval: January 10, 2018 Revised Dates: April 11, 2018 CRITERIA FOR PRIOR AUTHORIZATION PROVIDER GROUP Pharmacy Opioid Products Indicated for Pain Management MANUAL GUIDELINES All dosage forms
More informationPrescription Drugs MODULE 5 ALLIED TRADES ASSISTANCE PROGRAM. Preventative Education: Substance Use Disorder
Prescription Drugs MODULE 5 ALLIED TRADES ASSISTANCE PROGRAM Preventative Education: Substance Use Disorder Misuse of prescription pain relievers is, after marijuana use, the second most common form of
More informationThe Clean Water Agency s Unique Role in Solving a Deadly National Crisis By Cynthia Finley
TAKE BACK RESPONSIBILITY 56 The Clean Water Agency s Unique Role in Solving a Deadly National Crisis By Cynthia Finley 57 T he sheer numbers of drug abuserelated deaths in the US are striking and sobering.
More informationPrescription Drug Monitoring Program Update. Rebecca R. Poston, BPharm., MHL Program Manager August 26, 2017
Prescription Drug Monitoring Program Update Rebecca R. Poston, BPharm., MHL Program Manager August 26, 2017 Objectives Brief historical overview of opioids Review of PDMP information Discuss ideas from
More information9/3/2013. Presentation Objective. Prescription Drug Abuse Statistics Prescription Drug Abuse Statistics. Pharmaceutical Drugs and the Environment
Presentation Objective Background - Why do we need a regulation for the disposal of controlled substances. Disposal of Controlled Substances DEA Notice of Proposed Rulemaking AHMP 2013 National Conference
More informationSession VI. SAFE Opioid Prescribing Strategies. Assessment. Fundamentals. Education. Presenter Disclosure Information. Presenting Faculty
Presenter Disclosure Information SAFE Opioid Prescribing Strategies. Assessment. Fundamentals. Education 4:15 5pm Getting the Most Clinical Insights from Specific ER/LA Product Information Sources SPEAKERS
More informationAETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization
AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization Policy applies to all formulary and non-formulary schedules II V opioid narcotics, including tramadol and codeine, as
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.259 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Transmucosal Immediate Release Fentanyl Products Reference Number: CP.HNMC.211 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important
More informationTexas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationDuragesic patch. Duragesic patch (fentanyl patch) Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.31 Subject: Duragesic patch Page: 1 of 6 Last Review Date: March 18, 2016 Duragesic patch Description Duragesic patch (fentanyl
More informationOpioid Abuse in Iowa Rx to Heroin. Iowa Governor s Office of Drug Control Policy January 2016
1 Opioid Abuse in Iowa Rx to Heroin Iowa Governor s Office of Drug Control Policy January 2016 Why Is This Important? 2 3 National Rx Painkiller Trends CDC, 2013 4 National Rx-Heroin Trends NIH, 2015 5
More informationOXYCONTIN Diversion & Abuse Drug Enforcement Administration Office of Diversion Control October 2003
OXYCONTIN Diversion & Abuse Office of Diversion Control October 2003 OXYCONTIN OxyContin is a controlled release form of Schedule II oxycodone Manufactured in tablet form and intended for oral ingestion
More informationOverview of Current Medicine Take-Back Efforts
Overview of Current Medicine Take-Back Efforts Margaret Shield PhD Community Environmental Health Strategies LLC www.cehstrategies.com 206-499-5452 margaret.shield@cehstrategies.com June 16, 2017 Secure
More informationMAINE OFFICE OF ATTORNEY GENERAL. A Legal Guide to Safely and Successfully Conducting a Collection Event for Unwanted Prescription Medications
MAINE OFFICE OF ATTORNEY GENERAL A Legal Guide to Safely and Successfully Conducting a Collection Event for Unwanted Prescription Medications Wear it out, make it do, or do without -- Old New England Saying
More informationMedication Assisted Treatment
Meeting the Needs of Your Clients: Building Competencies in Mental Health and Addiction Services Medication Assisted Treatment November 5, 2018 In partnership with: House Keeping Because this is a webinar,
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 3053-9 Program Step Therapy Long Acting Opioids Medication Includes both brand and generic versions of the listed products unless
More informationEXTENDED RELEASE OPIOID DRUGS
RATIONALE FOR INCLUSION IN PA PROGRAM Background Hydrocodone (Hysingla ER, Vantrela ER, Zohydro ER), hydromorphone (Exalgo), morphine sulfate (Arymo ER, Avinza, Embeda, Kadian, MorphaBond, MS Contin),
More informationOpioid Analgesic Treatment Worksheet
Opioid Analgesic Treatment Worksheet Aetna Better Health of Louisiana Fax: 1 844 699 2889 www.aetnabetterhealth.com/louisiana/providers/pharmacy LA Legacy Fee for Service (FFS) Medicaid Fax: 1 866 797
More informationOpioid Capture in the AHSQC Can we reduce use by measuring it? Michael Reinhorn MD, MBA, FACS Dept of Surgery, Newton Wellesley Hospital
Opioid Capture in the AHSQC Can we reduce use by measuring it? Michael Reinhorn MD, MBA, FACS Dept of Surgery, Newton Wellesley Hospital Disclosure Davol/Bard Consultant Medtronic Physician Advisory Honorarium
More informationPequot Health Care Opioid Analgesic Quantity Program*
Pequot Health Care 1 Annie George Drive Mashantucket, CT 06338 Phone: 1-888-779-6638 Fax: 1-860-396-6494 Pequot Health Care Opioid Analgesic Quantity Program* Effective January 2018 *Quantity Program limits
More informationThe Unseen Consequences of Prescription Drug Abuse. Stephen Loyd, M.D.
The Unseen Consequences of Prescription Drug Abuse Stephen Loyd, M.D. Stephen Loyd, M.D. Receives no commercial support, in any form, from pharmaceutical companies or anyone else Medical Director for Substance
More informationOpiate/Benzodiazepine/Muscle Relaxant Combinations
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Opiate/Benzodiazepine/Muscle Relaxant Combinations Clinical Edit Information Included in this Document Drugs requiring prior authorization:
More informationHydrocodone 10mg vs oxycodone 10 mg. What is the difference between oxycontin and oxycodone hcl 1 acetaminophen with oxycodone and roxicodone 5mg
TE Te Hydrocodone 10mg vs oxycodone 10 mg What is the difference between oxycontin and oxycodone hcl 1 acetaminophen with oxycodone and roxicodone 5mg Manufacturer of oxycodone hcl 15 mg tablet side effects
More informationPrior Authorization Opioid Overutilization 2017
Drugs Requiring Prior Authorization Label Name ACETAMINOPHEN/CAFFEINE/DIHYDROCODEINE CAPSULE ACETAMINOPHEN/CODEINE SOLUTION ACETAMINOPHEN/CODEINE TABLET ASCOMP/CODEINE CAPSULE BUTALBITAL/CAFFEINE/ACETAMINOPHEN/CODEINE
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Opioid Therapy Table of Contents Coverage Policy... 1 General Background... 4 Coding/Billing Information... 7 References... 7 Effective Date..1/1/2018 Next
More informationBree Collaborative AMDG Opioid Prescribing Guidelines Workgroup. Opioid Prescribing Metrics - DRAFT
Bree Collaborative AMDG Opioid Prescribing Guidelines Workgroup Opioid Prescribing Metrics - DRAFT Definitions: Days Supply: The total of all opioid prescriptions dispensed during the calendar quarter
More informationSlide 1. Slide 2. Slide 3. Opioid (Narcotic) Analgesics and Antagonists. Lesson 6.1. Lesson 6.1. Opioid (Narcotic) Analgesics and Antagonists
Slide 1 Opioid (Narcotic) Analgesics and Antagonists Chapter 6 1 Slide 2 Lesson 6.1 Opioid (Narcotic) Analgesics and Antagonists 1. Explain the classification, mechanism of action, and pharmacokinetics
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Opioids, Extended Release (ER) Page 1 of 12 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Opioids, Extended Release (ER) Prime Therapeutics will review Prior Authorization
More informationMedication Disposal: Questions and Answers
of 7 3/2/6 :6 PM U.S. Food and Drug Administration Protecting and Promoting Your Health Medication Disposal: Questions and Answers For safety reasons, FDA recommends that a few, select medicines be disposed
More informationPediatric Toxicology Update
Pediatric Toxicology Update Suzan S Mazor MD Associate Professor Pediatric Emergency Medicine Medical Toxicology Seattle Children s Hospital University of Washington School of Medicine Washington Poison
More informationLimitations of use: Subsys may be dispensed only to patients enrolled in the TIRF REMS Access program (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.21 Subject: Subsys Page: 1 of 5 Last Review Date March 17, 2017 Subsys Description Subsys (fentanyl
More informationOpioid Step Policy. Description. Section: Prescription Drugs Effective Date: April 1, 2018
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Opioid Step Policy Page: 1 of 6 Last Review Date: March 16, 2018 Opioid Step Policy Description
More informationOpioids, Extended Release (ER) Quantity Limit Criteria Program Summary
Opioids, Extended Release (ER) Quantity Limit Criteria Program Summary This program applies to Commercial, GenPlus, NetResults A series, Netresults F series and Health Insurance Marketplace. Belbuca is
More informationDHCS Tribal MAT Project
DHCS Tribal MAT Project Melissa Eidman & Valentine Antony California Consortium for Urban Indian Health August 2018 CaliforniaConsortiumforUrbanIndianHealth CCUIH StrengtheningTheOrganizationsThatStrengthenOurCommunities
More informationOpioid Prescription and Illicit Drug Overdoses: On the Rise
Opioid Prescription and Illicit Drug Overdoses: On the Rise Cindy Haynes, MSA-PA, CHES Chronic Pain Program Coordinator Northern Piedmont Community Care Duke Division of Community Health Objectives Define
More information